For years, the narrative surrounding classic psychedelics—particularly psilocybin—has been one of profound, almost miraculous transformation. In the eyes of many researchers, advocates, and patients, these substances promised to upend the status quo of mental health treatment, offering a potential "cure" where traditional pharmaceuticals had failed. However, as the hype meets the rigorous, unforgiving reality of large-scale clinical trials and real-world application, a more nuanced, and perhaps sobering, picture is emerging.
Recent data suggests that psilocybin may not be the panacea once envisioned. Instead, it may join the ranks of existing antidepressants: a useful tool for some, but one that offers only incremental gains rather than the revolutionary breakthroughs initially advertised.
The Ghost of Prozac: A Historical Parallel
The trajectory of psychedelic medicine is beginning to look hauntingly familiar to the history of selective serotonin reuptake inhibitors (SSRIs). In the late 1980s, the introduction of fluoxetine (Prozac) was accompanied by a wave of cultural fervor. Media outlets heralded it as a "wonder drug," and the psychiatric community largely embraced the "chemical imbalance" theory of depression—the idea that a simple deficiency in serotonin could be corrected with a daily pill.
Decades later, that narrative has collapsed. A pivotal 2023 systematic review in Molecular Psychiatry found no robust evidence to support the hypothesis that depression is caused by lowered serotonin activity. Furthermore, the real-world performance of SSRIs proved far less impressive than the early, idealized clinical trials suggested. The landmark STAR*D trial—the largest of its kind—revealed that only about a third of patients achieved remission on their first medication. By the time patients reached their second or third drug, the success rates remained stubbornly modest.
As we look at the current state of psychedelic research, we are seeing the same cycle of high expectations followed by a cooling of clinical results. The danger, experts warn, is that by repeating the mistakes of the past, the field risks overselling a therapeutic intervention that is, at its core, a medicine of limited, albeit real, utility.
A Chronology of Cooling Expectations
The path from early promise to current reality has been a long, often bumpy road.
- 2020–2021: The Era of High Hopes: Early studies produced eye-popping results. A 2021 Johns Hopkins study of 24 patients with major depression reported a 71% response rate and 54% remission four weeks after two psilocybin sessions. A head-to-head study against escitalopram showed similarly high response rates. These figures galvanized the industry, attracting massive venture capital and public interest.
- 2022–2024: The Reality of Rigor: As trial sizes increased, the "effect size" began to shrink. Compass Pathways’ Phase 2b trial for treatment-resistant depression (TRD) saw response rates slide from 37% at the start to 20% by the 12-week mark.
- 2025–2026: The Pivotal Threshold: Compass Pathways reported that their Phase 3 trials achieved primary endpoints. However, the separation from the control group was modest, and the company relied on a 25% response threshold—a significantly lower bar than the traditional 50% used in standard psychiatric studies.
- The Present Day: Recent real-world data from the University Hospital of Psychiatry in Zurich shows response rates hovering around 33% and remission at 22%. These numbers are nearly identical to the benchmarks established by decades of SSRI research.
Analyzing the Supporting Data
The discrepancy between early, small-scale studies and more recent, larger trials is often attributed to "placebo inflation" and participant expectancy. Because psychedelic experiences are so profound and distinct, patients in clinical trials are often acutely aware of whether they have received the active drug or a placebo, which can skew self-reported outcomes on depression scales.
Recent meta-analyses have begun to strip away this optimism. A study published in JAMA Network Open by Hieronymus and colleagues compared active-arm response rates for psilocybin, SSRIs, and esketamine. They found striking parity: 48% for psilocybin, 46% for SSRIs, and 52% for esketamine.
Perhaps more damaging to the "miracle drug" narrative is the research published in JAMA Psychiatry by Williams, Barnett, and Szigeti. By treating psychedelic-assisted therapy trials as effectively open-label, the authors compared them to open-label antidepressant trials. The result? There was no significant difference in efficacy. The "psychedelic advantage" disappeared when the studies were placed on an equal footing.
Rotem Petranker, Ph.D., director of the Canadian Centre for Psychedelic Science, remains a voice of measured skepticism. Having once been an optimist about microdosing, his own research has led him to rethink those assumptions. "I used to think a dose so small it’s unnoticeable could still be effective," Petranker notes. "I don’t really think that anymore." His team’s recent large-scale trial on microdosing showed that both the drug and placebo groups improved, suggesting that much of the perceived benefit may be driven by psychological factors rather than pharmacological ones.
The Cautionary Tale of MDMA
The struggle to gain regulatory approval for psychedelic-assisted therapy is not unique to psilocybin. The case of MDMA-assisted therapy for PTSD serves as a stark warning. Lykos Therapeutics (formerly MAPS) saw their application rejected by the FDA in 2024, with the agency demanding an entirely new Phase 3 trial.
The rejection was a wake-up call for the entire industry. The FDA cited significant issues with trial design, the difficulty of blinding participants, and the complexities of bundling a drug with intensive psychotherapy. As noted by Philip Harvey and Charles Nemeroff in Neuropsychopharmacology, the reasons for the MDMA rejection are directly applicable to classical psychedelics. The "package deal" approach—where the drug is inextricably linked to hours of expensive, specialized therapy—poses massive logistical and financial hurdles for healthcare systems, even if the drug itself were to be approved.
Implications for Future Psychiatric Care
Where does this leave us? The consensus among objective observers is that we must shift our expectations. The rhetoric of "curing" depression is being replaced by a more pragmatic view: psychedelics are simply another tool in the psychiatric toolkit.
1. From Miracle to Tool
If psilocybin is approved by the FDA—which many, including researchers at Johns Hopkins, anticipate it will be—it will likely be positioned as a second- or third-line treatment for treatment-resistant populations. It will not be a first-line alternative to daily antidepressants, but rather a specialized intervention for those who have failed to respond to conventional options.
2. The Need for "Slow Science"
Petranker and others are calling for a move away from "bombastic" marketing and toward rigorous, slow science. The field needs larger, more diverse cohorts, better control groups, and longer-term data to understand not just whether these drugs work, but for whom they work, and for how long. The current record—roughly 1,500 people assessed in clinical trials over 20 years—is, in the context of global mental health, remarkably thin.
3. Redefining Success
The focus must shift from the "psychedelic experience" to the clinical outcomes. If a patient experiences a mystical breakthrough but remains depressed, is the treatment successful? The current trend toward focusing on "dysfunctional attitudes" and functional improvement rather than just mood scores suggests that the field is beginning to ask more sophisticated questions about what "wellness" actually looks like.
Conclusion: A Realistic Path Forward
The narrative of the "psychedelic revolution" is undergoing a necessary evolution. As the initial bloom of enthusiasm fades, it is being replaced by the hard, incremental work of clinical pharmacology. This is not a failure of the drugs themselves, but a failure of the unrealistic hype that surrounded them.
If psilocybin provides a meaningful, albeit modest, benefit to a subset of patients who have been failed by every other intervention, it is a significant medical achievement. But it is not a revolution. It is an evolution. By embracing this reality, researchers and policymakers can build a more sustainable framework for mental health care—one that is rooted in evidence rather than expectation, and one that offers patients genuine, tempered hope rather than the promise of a miracle that may never materialize.
The future of psychiatry will not be found in a single, magical molecule, but in the slow, meticulous integration of diverse treatments into a personalized, patient-centered model of care. The "psychedelic summer" may be cooling into a long, productive autumn of scientific inquiry—and that, perhaps, is exactly what the field needs.
About the Author
